Evonik's Strategic Pivot Gains Market Favor Amid Dividend Reset

Evonik's restructuring plan gains analyst upgrades from Goldman Sachs & Oddo BHF, despite a dividend cut to fund debt reduction and Asian investments. Shares have risen over 18%.

While Evonik's decision to reduce its traditionally stable dividend represents a significant shift for shareholders, the specialty chemicals group is receiving notable endorsement from major financial institutions. The company's comprehensive restructuring plan, designed to bolster long-term profitability, is being met with a wave of analyst upgrades, suggesting the market views the tough measures as a necessary step forward.

Analyst Upgrades Signal Confidence

Leading investment banks have recently refreshed their outlook on the MDAX-listed firm. Both Goldman Sachs and Oddo BHF raised their price targets to €20. According to Goldman Sachs analyst Georgina Fraser, the revision is driven by improved prospects in future technology segments. The analyst's note suggests that operational earnings will be supported by price increases and favorable currency effects. This optimistic stance aligns with recent trading activity; Evonik's shares have already appreciated by more than 18% over the preceding 30-day period.

A Cautious Note and a New Dividend Framework

Not all market observers share this unqualified positive view. Barclays has maintained a more conservative price target of €17, citing concerns that geopolitical tensions in the Middle East could disrupt supply chains and energy supplies.

Concurrently, the company's management is implementing a new financial policy that requires concessions from investors. For the 2025 fiscal year, the dividend will be cut from €1.17 to a flat €1.00 per share. Starting in 2026, a dynamic payout ratio will take effect, distributing between 40% and 60% of adjusted group net income. Capital preserved by this move is earmarked for debt reduction and strategic investments, particularly in the Asian market.

Cost-Cutting Drive and Insider Purchases

To secure lasting profitability, Evonik's executive board is advancing its "Evonik Tailor Made" efficiency program. The initiative aims to eliminate 2,000 positions globally by the end of 2026, generating annual savings of €400 million. Management confidence in this roadmap was demonstrated through recent transactions. In late March, members of both the executive and supervisory boards purchased company shares in a price range between €16.30 and €16.50.

The next key milestone for investors will be the quarterly results presentation on May 8, 2026. This report will need to demonstrate whether the operational strength forecast by optimists is materializing and will be crucial for supporting the full-year guidance for adjusted EBITDA, which is set between €1.7 billion and €2.0 billion.